Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when URGN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsUroGen settles Jelmyto patent suit with Teva, generic entry set for September 2030
Filed June 2, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
high
UroGen will allow Teva to launch generic Jelmyto on September 15, 2030, ending patent litigation and setting a firm date when generic competition will erode the company's market exclusivity for its key product.
Item 8.01 verify on EDGAR → -
medium
Settlement terminates all pending patent litigation in Delaware federal court, eliminating legal costs and uncertainty around Jelmyto's patent protection through 2030.
Item 8.01 verify on EDGAR → -
low
Agreement requires standard antitrust review by FTC and DOJ, though regulatory challenges to pharmaceutical patent settlements are uncommon.
Item 8.01 verify on EDGAR →
Summary
UroGen Pharma has settled its patent dispute with Teva Pharmaceuticals over Jelmyto, its mitomycin treatment for upper urinary tract cancer. Under the agreement, Teva can launch a generic version starting September 15, 2030, if FDA-approved. This ends costly litigation but also puts a definitive expiration date on UroGen's monopoly pricing power for Jelmyto.
For investors, this settlement provides clarity: UroGen has roughly four years of protected revenue from Jelmyto before facing generic competition. The company avoids the risk and expense of continued litigation, but the 2030 date means management must either diversify revenue streams or prepare for a significant hit to Jelmyto sales when generics arrive.
Watch for UroGen's pipeline progress and any acquisitions or partnerships aimed at offsetting the inevitable Jelmyto revenue decline. The company's ability to launch new products or expand other revenue sources before September 2030 will determine whether this settlement represents a manageable transition or a looming cliff.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 2, 2026, UroGen Pharma Ltd. and UroGen Pharma Inc. (collectively, “the Company”) issued a press release announcing that the Company entered into a settlement and license agreement (the “Agreement”) with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. (collectively, “Teva”) that resolves the patent litigation between the parties related to Jelmyto® (mitomycin) for pyelocalyceal solution.
UroGen entered into a settlement agreement with Teva that resolves ongoing patent litigation related to Jelmyto, the Company's mitomycin product for pyelocalyceal solution. This settlement ends legal disputes that arose from Teva's attempt to bring a generic version to market before patent expiration.
Added in current filing · verify on EDGAR →
Under the terms of the Agreement, the Company will grant Teva a non-exclusive license to sell Teva’s generic version of Jelmyto beginning on September 15, 2030, if approved by the FDA, unless certain limited circumstances customarily included in these types of agreements occur.
UroGen will allow Teva to launch a generic version of Jelmyto starting September 15, 2030, subject to FDA approval. This sets a definitive timeline for when generic competition will enter the market, which will likely impact UroGen's Jelmyto revenue and market exclusivity after that date.
Added in current filing · verify on EDGAR →
In accordance with the Agreement, the parties will terminate all ongoing patent litigation between the Company and Teva regarding Jelmyto patents pending in the U.S. District Court for the District of Delaware.
All pending patent litigation between UroGen and Teva in Delaware federal court will be terminated as part of the settlement. This eliminates legal uncertainty and associated costs for both parties.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
The settlement agreement requires antitrust review by the FTC and DOJ, which is standard for pharmaceutical patent settlements. There is a possibility, though typically low, that regulators could challenge the agreement if they view it as anticompetitive.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify